Services for Pharmaceutical products, Analytical Methods, Ecotoxicological studies, Environmental fate and behaviour studies #pharma #industry #news

Posted On May 2 2017 by

#pharmaceutical products # PHARMACEUTICAL PRODUCTS A Medicinal product is defined as any substance or combination of substances presented for treating or preventing disease in human beings. Any substance or combination of substances which may be administered to human beings with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in human beings is likewise considered a medicinal product. Medicinal products are regulated by the Directive 2001/83/EC. According to the implementation of this Directive the evaluation of the potential environmental risks posed by medicinal products should be submitted, their environmental impact should be assessed and, …


Services for Pharmaceutical products, Analytical Methods, Ecotoxicological studies, Environmental fate and behaviour studies #pharma #consultant

Posted On Apr 13 2017 by

#pharmaceutical products # PHARMACEUTICAL PRODUCTS A Medicinal product is defined as any substance or combination of substances presented for treating or preventing disease in human beings. Any substance or combination of substances which may be administered to human beings with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in human beings is likewise considered a medicinal product. Medicinal products are regulated by the Directive 2001/83/EC. According to the implementation of this Directive the evaluation of the potential environmental risks posed by medicinal products should be submitted, their environmental impact should be assessed and, …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #new #pharmaceutical #companies

Posted On Apr 2 2017 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #ipca #pharma

Posted On Mar 20 2017 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Services for Pharmaceutical products, Analytical Methods, Ecotoxicological studies, Environmental fate and behaviour studies #generic #pharmaceuticals #companies

Posted On Jan 10 2017 by

#pharmaceutical products # PHARMACEUTICAL PRODUCTS A Medicinal product is defined as any substance or combination of substances presented for treating or preventing disease in human beings. Any substance or combination of substances which may be administered to human beings with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in human beings is likewise considered a medicinal product. Medicinal products are regulated by the Directive 2001/83/EC. According to the implementation of this Directive the evaluation of the potential environmental risks posed by medicinal products should be submitted, their environmental impact should be assessed and, …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #pharmaceutical #companies

Posted On Dec 14 2016 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #amag #pharma

Posted On Nov 23 2016 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #jobs #in #pharmaceutical #industry

Posted On Nov 13 2016 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Services for Pharmaceutical products, Analytical Methods, Ecotoxicological studies, Environmental fate and behaviour studies #pharmaceutical #industry #news

Posted On Oct 30 2016 by

#pharmaceutical products # PHARMACEUTICAL PRODUCTS A Medicinal product is defined as any substance or combination of substances presented for treating or preventing disease in human beings. Any substance or combination of substances which may be administered to human beings with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in human beings is likewise considered a medicinal product. Medicinal products are regulated by the Directive 2001/83/EC. According to the implementation of this Directive the evaluation of the potential environmental risks posed by medicinal products should be submitted, their environmental impact should be assessed and, …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #pharmaceutical #sales #industry

Posted On Oct 28 2016 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …